AI-Powered Research

Conditions: Chronic Myeloproliferative Disorders
Brain and Central Nervous System Tumors
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Pain
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific
Lymphoma
Lymphoproliferative Disorder

Interventions: Drug: methadone hydrochloride
Drug: morphine sulfate
Drug: oxycodone hydrochloride

First Posted Date: 2008-08-01

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00726830

Locations: 🇺🇸
Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

Not Applicable

Terminated

Conditions: Brain Tumor

Interventions: Procedure: Visualase® Thermal Therapy System

First Posted Date: 2008-07-23

Last Posted Date: 2012-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00720837

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Sunitinib
Procedure: Nephrectomy

First Posted Date: 2008-07-15

Last Posted Date: 2024-10-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00715442

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

8-Chloro-Adenosine in Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia
Chronic Lymphocytic Leukemia

Interventions: Drug: 8-Chloro-Adenosine

First Posted Date: 2008-07-14

Last Posted Date: 2016-10-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00714103

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Sinonasal Undifferentiated Carcinoma
Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8
Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8
Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8
Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8

Interventions: Drug: Carboplatin
Other: Chemoradiotherapy
Drug: Cisplatin
Procedure: Definitive Surgical Resection
Drug: Docetaxel
Drug: Fluorouracil
Procedure: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2008-06-30

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00707473

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Continuous Glucose Monitoring in Critically Ill

Not Applicable

Terminated

Conditions: Diabetes

Interventions: Device: Guardian® blood-sugar monitoring device

First Posted Date: 2008-06-30

Last Posted Date: 2020-03-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00707434

Locations: 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States

and more 3 locations

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Phase 2

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Natural Killer Cell Infusion
Drug: Mesna
Drug: Interleukin-2

First Posted Date: 2008-06-16

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00698009

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Ann Arbor Stage IV Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Ann Arbor Stage III Small Lymphocytic Lymphoma
Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
Ann Arbor Stage IV Marginal Zone Lymphoma
Ann Arbor Stage III Grade 1 Follicular Lymphoma
Ann Arbor Stage III Marginal Zone Lymphoma
Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma
Ann Arbor Stage IV Small Lymphocytic Lymphoma